DarioHealth Corp.
No enriched coverage for $DRIO in the last 7 days.
No SEC Form 4 filings for $DRIO in the last 30 days.
See all $DRIO insider activity →DarioHealth (DRIO) secured a contract with a major New Jersey health plan covering 1.5 million lives, via partner Amwell. The deal, part of Dario's channel strategy, is expected to launch and generate revenue in Q1 2027, expanding its reach into large health plan populations.
DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Lawrence Leisure notified the Board of Directors (the “Board”) of DarioHealth Corp. (the “Company”) o
DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on July 10, 2026, the temporary medical leave of absence of Steven Nelson, President and Chief Com
Recent DRIO coverage spans earnings, corporate actions and technology.
The contract expands DarioHealth's addressable market and should boost future revenue streams.
Board change may affect governance perception but no immediate financial impact.
The agreement creates a modest dilution risk and signals the company’s willingness to use equity for talent.
The call provides a concrete revenue-conversion roadmap and margin drivers tied to the B2B2C pivot, which can re-rate near-term growth and profitability expectations.
The transcript is a forward-looking commercial thesis around DarioIQ monetization and cost leverage, but it provides no new quarterly numbers in the excerpt.
AlphAI scores every news story that mentions DRIO with an AI model for sentiment and relevance, and aggregates insider trades from DarioHealth Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DarioHealth (DRIO) secured a contract with a major New Jersey health plan covering 1.5 million lives, via partner Amwell. The deal, part of Dario's channel strategy, is expected to launch and generate revenue in Q1 2027, expanding its reach into large health plan populations.
2 min readDarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Lawrence Leisure notified the Board of Directors (the “Board”) of DarioHealth Corp. (the “Company”) o
1 min readDarioHealth Corp. (DRIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on July 10, 2026, the temporary medical leave of absence of Steven Nelson, President and Chief Com
1 min readDarioHealth Corp. discussed its Q2 2026 earnings call, saying it is shifting from an investment phase to compounding growth via account depth, partner distribution, AI (DarioIQ), and value chain participation. It exited lower-quality pharma services for higher-margin B2B2C revenue. Contracted/late-stage ARR of $13.1M should convert in H2 2026, mainly 2027. Pro forma cash is $36.8M after a $22.8M registered direct financing.
6 min readDarioHealth (DRIO) CEO Erez Raphael discussed the company’s positioning and growth drivers in a Q2 2026 earnings call transcript. He described a multi-condition digital health platform with FDA-cleared connected devices, proprietary longitudinal data (about 13 billion data points), and AI (DarioIQ). The company said DarioIQ could add about 10% to 15% to recurring revenues from existing customers over time.
7 min readDarioHealth (NASDAQ:DRIO) said in its Q2 earnings call that sequential revenue fell due to post-transformation cleanup and closure of its pharmaceutical channel, with management expecting momentum to build in Q3-Q4 and accelerate in Q1 2027. The company highlighted channel-partner account growth, AI DarioIQ potential to lift recurring revenue 10%-15%, and $14M cash at June 30 plus $22.8M net proceeds from July financing.
6 min readDarioHealth Corp. (NASDAQ: DRIO) reported Q2 2026 revenue of $5.2 million, down from $5.6 million in Q1 2026, citing discontinuation of some pharmaceutical-related business. Gross margin rose to 62% (from 57% in Q1 2026). Operating loss improved 30% YoY and 11% QoQ. Pro forma cash was $36.8 million after July 2026 at-the-market financing.
6 min readDarioHealth Corp. (NASDAQ: DRIO) said it expanded its provider-backed cardiometabolic platform with two new programs, Dario Women and Dario Sleep. The company expects rollouts to Fortune 500 clients in Fall 2026 and recurring revenue per engaged member per month to start in Q4 2026, with provider-backed care revenue expected end-2026 into early 2027.
4 min readDarioHealth Corp. (NASDAQ: DRIO) launched an Integrated GLP-1 Program combining its AI chronic care platform with provider-backed clinical care from Beluga Health. The offering adds licensed evaluation, prescribing of FDA-approved GLP-1s, and ongoing oversight in one platform. Availability is expected in Fall 2026, with revenue starting late 2026 and ramping through 2027.
4 min readMatheis Dennis purchased 14,430 shares of DarioHealth Corp. (DRIO) at $6.93 on 2026-07-23.
1 min read
